66. IgA腎症 IgA nephropathy Clinical trials / Disease details


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02571842
(ClinicalTrials.gov)
January 20126/10/2015Rituximab in Recurrent IgA NephropathyA Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation PathologyRecurrent IgA NephropathyDrug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroidsChulalongkorn UniversityNULLRecruiting18 Years70 YearsBoth30Phase 4Thailand
2ChiCTR-TRC-09000338
2009-04-012009-02-23Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathyFull dose of RASS blockade versus steroids therapy in patients with IgA nephropathy IgA nephropathyGroup A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;The First Affiliated Hospital of Zhejiang UniversityNULLCompleted1870MaleGroup A:60;Group B:60;China
3ChiCTR-TRC-06000004
2006-01-012006-09-14ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trialACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial primary IgA nephropathygroup 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB;The First Hospital, Peking UniversityNULLCompleted1665Bothgroup 1:78;group 2:78;China
4NCT00378443
(ClinicalTrials.gov)
January 200619/9/2006ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCTGlomerulonephritis, IGADrug: prednisone + Inhibace/Cozaar;Drug: Inhibace/CozaarPeking UniversityNULLActive, not recruiting16 Years65 YearsBothN/ANULL
5NCT00318474
(ClinicalTrials.gov)
January 200224/4/2006Mycophenolate Mofetil (MMF) in Patients With IgA NephropathyA Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA NephropathyIgA NephropathyDrug: Mycophenolate Mofetil (MMF);Drug: MMF Placebo;Drug: ACEi;Drug: FOSSt. Joseph's Hospital and Medical Center, PhoenixNULLTerminated7 Years70 YearsAll184Phase 3United States